P32/98 (Ile-thiazolidide) is a specific, competitive transition-state substrate analog inhibitor of dipeptidyl peptidase IV (DPIV; DPPIV; CD26), with a Ki of 130 nM. Useful in diabetes research. Has been used in vivo and in tissue culture.
Product Details
Alternative Name: | 3-N-[((2S,3S)-2-Amino-3-methylpentanoyl]-1,3-thiazolidine . hemi-fumarate |
|
Formula: | C9H18N2OS . 0.5 C4H4O4 |
|
MW: | 260.4 |
|
CAS: | 136259-20-6 |
|
Purity: | ≥98% (TLC, free base) |
|
Appearance: | White solid. |
|
Solubility: | Soluble in water (20mg/ml) or DMSO (25mg/ml). |
|
Application Notes: | May be used to inhibit GLP-1 breakdown in blood, plasma and serum samples at a concentration of 1 mM. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats: G. Giannocco, et al.; Eur. J. Pharmacol.
698, 74 (2013),
Application(s): Assay using rat skeletal and heart muscle,
Abstract;
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1: R. Crajoinas, et al.; Am. J. Physiol. Renal Physiol.
301, F355 (2011),
Application(s): Assay using rat urine and blood,
Abstract;
Full Text
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats: J.A. Pospisilik, et al.; Diabetes
52, 741 (2003),
Application(s): Oral gavage,
Abstract;
Full Text
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats: J.A. Pospisilik, et al.; Diabetes
51, 943 (2002),
Application(s): Oral gavage,
Abstract;
Full Text